Workflow
医美定价权之争
icon
Search documents
新氧又上黑名单,医美再现定价权之争
Jing Ji Guan Cha Wang· 2025-11-29 11:15
Core Viewpoint - The conflict between New Oxygen and upstream company Puli Yan regarding the pricing and distribution of the "Tongyan Needle" has intensified, highlighting the challenges of profit distribution within the medical beauty industry [2][5]. Group 1: Conflict Background - Puli Yan has listed 79 medical institutions, including 46 New Oxygen clinics, as unauthorized and non-cooperative, claiming they disrupt the pricing system by selling products below the official guidance price [2][3]. - New Oxygen responded by asserting that all products are legally sourced and that their clinics operate within the law, with qualified medical personnel [3][10]. Group 2: Product Details - The "Tongyan Needle," officially known as "Poly-L-Lactic Acid (PLLA) Facial Filler," is designed to stimulate collagen regeneration for facial contouring and wrinkle improvement [4]. - Puli Yan is one of several companies authorized to produce and sell this product in China, with others including Aimeike and Shengboma [4]. Group 3: Pricing Discrepancies - New Oxygen's pricing strategy significantly undercuts Puli Yan's guidance, with prices for the Tongyan Needle at New Oxygen clinics being approximately 60% lower than the official price [5][6]. - For instance, New Oxygen's "Miracle Tongyan 1.0" is priced at 5999 yuan per unit, while other institutions have sold it for as low as 4599 yuan, which is about 70% below the guidance price [5][6]. Group 4: Market Dynamics - The medical beauty industry is characterized by high profit margins, with upstream manufacturers historically controlling prices, leading to margins as high as 90% [7][8]. - New Oxygen aims to disrupt this model by reducing costs through supply chain integration and offering lower prices to attract consumers, thereby democratizing access to medical beauty services [9][10]. Group 5: Business Model and Challenges - New Oxygen's business model focuses on lowering customer acquisition costs and compressing high margins from upstream suppliers, with a goal of making medical beauty services more accessible [9][10]. - Despite the aggressive pricing strategy, New Oxygen has faced financial challenges, reporting losses in recent quarters as it expands its self-operated medical beauty centers [11][12].